基于细胞的免疫治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按疗法(自体细胞免疫疗法、嵌合抗原受体 (CAR) T 细胞疗法、基于树突状细胞的疫苗疗法)、主要适应症和地理位置进行细分。

市场快照

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 15.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

预计基于细胞的免疫治疗市场在预测期内的复合年增长率为 15.5%。细胞免疫疗法也称为过继细胞疗法,是一种利用免疫系统细胞治疗癌症的治疗形式。
免疫系统能够识别和消除被感染、受损或癌变的细胞。被称为杀伤性 T 细胞的免疫细胞对癌细胞起作用,因为它们能够与癌细胞表面上的抗原标记物结合。细胞免疫疗法利用杀伤性 T 细胞的天然能力,使它们对抗癌细胞。有时,这些 T 细胞在有效杀死癌细胞之前就被激活,并且可能没有足够的数量来对抗癌细胞。为了解决这些问题,肿瘤浸润淋巴细胞(TIL)是一种基于细胞的免疫疗法。
2018 年,世界卫生组织 (WHO) 估计全球有 1810 万新癌症病例和约 960 万例死亡。此外,全球五分之一的男性和六分之一的女性在其一生中患上癌症,八分之一的男性和十一分之一的女性死于该病。癌症患病率的上升、技术进步和新型靶向抗癌疗法的开发是基于细胞的免疫疗法市场的关键驱动因素。

报告范围

细胞免疫疗法也称为过继细胞疗法,是一种利用免疫系统细胞治疗癌症的治疗形式。基于细胞的免疫治疗市场按治疗、主要适应症和地理划分。

By Therapy
Autologous Cellular Immunotherapy
Chimeric Antigen Receptor (CAR) T-Cell Therapy
Dendritic Cell-based Vaccine Therapy
By Primary Indication
B-cell Malignancies
Prostate Cancer
Renal Cell Carcinoma
Liver Cancer
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

嵌合抗原受体 (CAR) T 细胞治疗领域有望在基于细胞的免疫治疗市场中占据主要市场份额

  • 嵌合抗原受体 (CAR) T 细胞疗法是癌症治疗的重大进步。在这种疗法中,患者自身的 T 细胞经过基因工程改造,可表达结合肿瘤抗原的人工受体。CAR-T 细胞疗法作用于 CD19 编码的癌症抗原,用于治疗 B 细胞癌。Yescarta 和 Kymriah 代表最近批准的 CAR T 细胞治疗产品,用于治疗 B 细胞恶性肿瘤,如非霍奇金淋巴瘤、急性淋巴细胞白血病、套细胞淋巴瘤、慢性淋巴细胞白血病和弥漫性大 B 细胞淋巴瘤。
  • 根据国际癌症研究机构 (IARC) 的数据,到 2040 年,预计癌症新病例将增长到每年 2750 万例。此外,预计未来 20 年全球癌症负担将增加 70%。
  • 嵌合抗原受体 (CAR) T 细胞治疗部门在基于细胞的免疫治疗市场中占有重要的市场份额,预计在预测期内将显示出类似的趋势。
  • 癌症患病率的上升、开发靶向抗癌疗法的技术进步以及为治疗目的而采用基于细胞的疗法是嵌合抗原受体 (CAR) T 细胞治疗领域的关键驱动因素。
Cell Based Immunotherapy Key trend 1

北美预计将在市场上占有重要份额,预计在预测期内也将如此

由于癌症发病率的上升和该地区对细胞疗法的认识不断提高,预计北美将在全球细胞免疫疗法市场占据主要市场份额。根据疾病控制和预防 (CDC) 的数据,美国每年有近 245,000 例女性乳腺癌和约 2,200 例男性确诊,美国每年约有 41,000 名女性和 460 名男性死于乳腺癌。此外,正在进行的癌症治疗研究、细胞疗法中先进技术的采用以及完善的医疗保健基础设施的存在也在很大程度上推动了整个区域市场的增长。

Cell Based Immunotherapy Market 2

竞争格局

基于细胞的免疫治疗市场具有综合竞争力,由少数主要参与者组成。就市场份额而言,目前很少有主要参与者占据市场主导地位。目前主导市场的一些公司是诺华公司、吉利德科学公司 (Kite Pharma)、Apac Biotech、Dendreon Pharmaceuticals LLC、JW CreaGene Co., Ltd 和 Green Cross Corp (GC Pharma)。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Cancer

      2. 4.2.2 Technological Advancement in Developing Target Based Anti-cancer Therapies

      3. 4.2.3 Launches and Approval of Different Cell-based Immunotherapy Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Technology

      2. 4.3.2 Lack of Awareness in the Developing Markets

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Therapy

      1. 5.1.1 Autologous Cellular Immunotherapy

      2. 5.1.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy

      3. 5.1.3 Dendritic Cell-based Vaccine Therapy

    2. 5.2 By Primary Indication

      1. 5.2.1 B-cell Malignancies

      2. 5.2.2 Prostate Cancer

      3. 5.2.3 Renal Cell Carcinoma

      4. 5.2.4 Liver Cancer

      5. 5.2.5 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Novartis AG

      2. 6.1.2 Gilead Sciences, Inc (Kite Pharma)

      3. 6.1.3 Apac Biotech

      4. 6.1.4 Dendreon Pharmaceuticals LLC

      5. 6.1.5 JW CreaGene Co., Ltd

      6. 6.1.6 Green Cross Corp (GC Pharma)

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Cell Based Immunotherapy Market market is studied from 2018 - 2026.

The Cell Based Immunotherapy Market is growing at a CAGR of 15.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Novartis AG, Gilead Sciences, Inc (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co., Ltd are the major companies operating in Cell Based Immunotherapy Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!